Presentation is loading. Please wait.

Presentation is loading. Please wait.

Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level.

Published byPatrycja Wasilewska Modified over 5 years ago

Similar presentations

Presentation on theme: "Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level."— Presentation transcript:

1 Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Red indicates tumors sensitive to cisplatin. Tumors with a germline mutation in BRCA1 or BRCA2 are excluded in A and B but included in C, represented as triangles. In B and C, BRCA1 transcript levels measured by qRT-PCR were z-transformed and combined by centering the values and dividing by the standard deviation within each trial. A, BRCA1 transcripts in resistant and sensitive tumors in the Cisplatin-2 cohort. B, BRCA1 expression in tumors by methylation status of the BRCA1 promoter region in the combined Cisplatin-1 and Cisplatin-2 cohorts. C, relationship of BRCA1 transcript level and NtAI in the combined Cisplatin-1 and Cisplatin-2 cohorts. Nicolai J. Birkbak et al. Cancer Discovery 2012;2: ©2012 by American Association for Cancer Research

Download ppt "Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level."

Similar presentations

DNA damage foci in irradiated cells.

DNA damage foci in irradiated cells.
BCR–ABL1 B-ALLs feature DNA methylation and expression signatures centered aroundIL2RA(CD25). BCR–ABL1 B-ALLs feature DNA methylation and expression signatures.

BCR–ABL1 B-ALLs feature DNA methylation and expression signatures centered aroundIL2RA(CD25). BCR–ABL1 B-ALLs feature DNA methylation and expression signatures.
PARPi combinations against HR-proficient tumors.

PARPi combinations against HR-proficient tumors.
PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.
Antitumor activity of BAY in patient-derived tumor models.

Antitumor activity of BAY in patient-derived tumor models.
Reduction of Sca-1 increases PPARγ expression.

Reduction of Sca-1 increases PPARγ expression.
Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.
The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.

The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.
Mechanisms of PARPi resistance in HR-deficient cells.

Mechanisms of PARPi resistance in HR-deficient cells.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Epigenetic regulation of miR-193b in liposarcomagenesis.

Epigenetic regulation of miR-193b in liposarcomagenesis.
Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.
Alterations related to androgen signaling.

Alterations related to androgen signaling.
Core promoter methylation in mediators of adipogenesis.

Core promoter methylation in mediators of adipogenesis.
A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.
Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
USP2a overexpression modifies the microRNA expression profile of prostate cells. USP2a overexpression modifies the microRNA expression profile of prostate.

USP2a overexpression modifies the microRNA expression profile of prostate cells. USP2a overexpression modifies the microRNA expression profile of prostate.
Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

Similar presentations

Ads by Google